Your browser doesn't support javascript.
loading
Whole-brain radiation therapy plus simultaneous integrated boost for brain metastases from breast cancers.
Zhang, Hongyan; Wu, Qiuji; Li, Li; Wang, Linwei; Zhong, Yahua.
Afiliación
  • Zhang H; Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.
  • Wu Q; Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.
  • Li L; Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.
  • Wang L; Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.
  • Zhong Y; Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei Province, China.
PeerJ ; 12: e17696, 2024.
Article en En | MEDLINE | ID: mdl-39011372
ABSTRACT

Background:

The effect of whole-brain radiation therapy (WBRT) plus simultaneous integrated boost (SIB) in brain metastasis from breast cancers has not been demonstrated.

Method:

In this single-center retrospective study, we reviewed consecutive breast cancer patients who developed brain metastasis and were treated with hypofractionated radiation therapy plus WBRT using intensity-modulated radiation therapy (IMRT)-SIB approaches. We analyzed clinical outcomes, prognostic factors and patterns of treatment failure.

Result:

A total of 27 patients were eligible for analysis. Four (14.8%) patients achieved clinical complete response and 14 (51.9%) had partial response of brain lesions. The other nine patients were not evaluated for brain tumor response. The median brain progression-free survival was 8.60 (95% CI [6.43-13.33]) months and the median overall survival was 16.8 (95% CI [13.3-27.7]) months. Three patients had in-field failure, five had out-field failure and two had in-field and out-field failure.

Conclusion:

WBRT plus SIB led to improved tumor control and clinical outcome in breast cancer patients with brain metastasis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Neoplasias de la Mama / Irradiación Craneana Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: PeerJ Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Neoplasias de la Mama / Irradiación Craneana Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: PeerJ Año: 2024 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos